Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
DMRAthis companyDamora Therapeutics, Inc.	$24.45	-0.15×	0.13×	0×	1.08×	776.2%	0.0%	0.0%	0.0%	-87.3%	-87.7%	-21.4%	0×	1.23×	0×	12.98×	0.0%	3	26.87	1	D+
COAGHemab Therapeutics Holdings, Inc. Common Stock	$46.98	-14.59×	-5.28×	0×	-12.12×	-92.6%	0.0%	0.0%	0.0%	36.2%	-37.8%	-6.6%	-0.01×	1.24×	0×	18.03×	0.0%	—	—	2	C+
GERNGeron Corporation	$0.99	-10.15×	3.9×	4.79×	-20.26×	-808.4%	97.4%	-29.3%	-46.7%	-38.0%	-11.3%	-12.6%	1.11×	-3.32×	-1.65×	4.66×	0.0%	1	-2.78	1	C-
INCYIncyte Corporation	$120.30	14.99×	3.73×	3.75×	9.23×	-2.4%	92.8%	26.1%	25.0%	24.9%	20.6%	7.0%	0.01×	-1.72×	553.04×	3.32×	0.0%	6	10.87	3	B+
IRONDisc Medicine, Inc.	$79.57	-13.21×	3.79×	0×	-13.05×	-97.1%	0.0%	0.0%	0.0%	-28.7%	-30.6%	-6.5%	0×	0.43×	-65.43×	21.94×	0.0%	1	18.78	2	C
KROSKeros Therapeutics, Inc.	$9.62	8.7×	2.5×	3.11×	5.22×	-547.0%	99.4%	28.9%	35.7%	28.7%	20.9%	14.0%	0.06×	-2.9×	0×	15.45×	0.0%	3	2.59	3	B
Peer median	—	-10.15×	3.73×	3.11×	-12.12×	-97.1%	92.8%	0.0%	0.0%	24.9%	-11.3%	-6.5%	0.01×	-1.72×	0×	15.45×	0.0%	2	6.73	2	—